Insights from the AHA 2025 Scientific Sessions

The panelists share their perspectives on key updates from the AHA 2025 Scientific Sessions that have implications for ASCVD management. They highlight ongoing efforts to achieve earlier and more aggressive LDL-C lowering, supported by data reinforcing the impact of cumulative LDL exposure on recurrent event risk. The experts discuss new findings from the VESALIUS trial, which evaluated evolocumab in patients without prior myocardial infarction or stroke, showing significant LDL-C reduction and suggesting potential benefit even in earlier stages of ASCVD. They also reference presentations on PCSK9 and siRNA-based therapies, which continue to demonstrate strong efficacy, safety, and adherence in real-world practice. The panel underscores the growing evidence for hospital-based initiation of lipid-lowering therapy to improve continuity of care. Collectively, these updates highlight a paradigm shift toward earlier intervention and sustained LDL-C reduction as essential strategies for preventing recurrent and first cardiovascular events.